Open AccessMetabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure
Author(s) -
Hunter Wynn G.,
Kelly Jacob P.,
McGarrah Robert W.,
Khouri Michel G.,
Craig Damian,
Haynes Carol,
Ilkayeva Olga,
Stevens Robert D.,
Bain James R.,
Muehlbauer Michael J.,
Newgard Christopher B.,
Felker G. Michael,
Hernandez Adrian F.,
Velazquez Eric J.,
Kraus William E.,
Shah Svati H.
Publication year - 2016
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.115.003190
Subject(s) - ejection fraction , heart failure , medicine , heart failure with preserved ejection fraction , cardiology , diastole , metabolomics , endocrinology , bioinformatics , blood pressure , biology
Background Metabolic impairment is an important contributor to heart failure ( HF ) pathogenesis and progression. Dysregulated metabolic pathways remain poorly characterized in patients with HF and preserved ejection fraction ( HF p EF ). We sought to determine metabolic abnormalities in HF p EF and identify pathways differentially altered in HF p EF versus HF with reduced ejection fraction ( HF r EF ). Methods and Results We identified HF p EF cases, HF r EF controls, and no‐ HF controls from the CATHGEN study of sequential patients undergoing cardiac catheterization. HF p EF cases (N=282) were defined by left ventricular ejection fraction ( LVEF ) ≥45%, diastolic dysfunction grade ≥1, and history of HF ; HF r EF controls (N=279) were defined similarly, except for having LVEF <45%. No‐ HF controls (N=191) had LVEF ≥45%, normal diastolic function, and no HF diagnosis. Targeted mass spectrometry and enzymatic assays were used to quantify 63 metabolites in fasting plasma. Principal components analysis reduced the 63 metabolites to uncorrelated factors, which were compared across groups using ANCOVA . In basic and fully adjusted models, long‐chain acylcarnitine factor levels differed significantly across groups ( P< 0.0001) and were greater in HF r EF than HF p EF ( P =0.0004), both of which were greater than no‐ HF controls. We confirmed these findings in sensitivity analyses using stricter inclusion criteria, alternative LVEF thresholds, and adjustment for insulin resistance. Conclusions We identified novel circulating metabolites reflecting impaired or dysregulated fatty acid oxidation that are independently associated with HF and differentially elevated in HF p EF and HF r EF . These results elucidate a specific metabolic pathway in HF and suggest a shared metabolic mechanism in HF along the LVEF spectrum.